The EyeMax Mono™ IOL Designed for AMD Patients to be Featured at the 2024 ESCRS and Euretina Annual Congresses in Barcelona
A summary of the presentations and papers featuring EyeMax Mono™ is included below.
Sharpview Ophthalmology Limited, a pioneer in the development and commercialisation of advanced intraocular lens technology for patients with age-related macular degeneration (AMD), is pleased to announce its participation in the European Society of Cataract and Refractive Surgeons (ESCRS) and the European Society of Retina Specialists (Euretina) annual congresses.
The company's revolutionary EyeMax Mono™ intraocular lens (IOL) will be featured in the official programmes of these prestigious events, taking place in Barcelona (Spain) on September 6-10, 2024, and September 19-22, 2024, respectively.
A summary of the presentations and papers featuring EyeMax Mono™ is included below.
Dr. Federico Badalà (Micro Chirurgia Oculare, Italy) will present both at ESCRS and at Euretina the results of its study on implanting the EyeMax Mono in 113 eyes from 86 patients with stable AMD and – this is of particular importance - visually insignificant cataracts. This approach provides a clearer understanding of the lens's effectiveness in improving vision for AMD patients, in isolation to the removal of the cataract.
Long-Term Safety And Efficacy of an Extended Macular Vision Intraocular Lens (IOL) In Patients with Stable AMD - Visually Insignificant Cataract Eyes
ESCRS: Session: Challenging Cataract Surgery
Date: Monday, 09 September 2024 / Time: 14:18 - 14:24 AM
Room: Free paper podium 1
Euretina: Audio-Narrated Free Paper
The results of the multicenter study from 7 European centers collating the post-market surveillance data of the EyeMax Mono implantation will be presented at ESCRS by Dr. Sebastian Beckers (Spain), as well as at Euretina by Dr. Jairo Hoyos Chacon (Spain).
Real-world outcomes of an extended macular vision IOL in age-related macular degeneration.
ESCRS: Session: Cataract surgery IOLs
Date: Monday, 09 September 2024 / Time: 14:30 - 14:36 AM
Room: Free paper podium 1
Euretina: Audio-Narrated Free Paper
--
In addition, the following studies will be featured in the respective congresses:
Johan Lønsmann Poulsen, Jacob Nielsen, Niels Vesti Nielsen (Denmark)
Evaluating the effectiveness of EyeMax Mono IOL for enhancing vision in mild to moderate age-related macular degeneration.
ESCRS: Session: Cataract surgery IOLs
Date: Monday, 09 September 2024 / Time: 15:25 - 15:30 AM
Room: Hall 6 & 7 - Pod 1
Boris Stanzel, Martin Bedersdorfer, Peter Szurman, Karl T. Boden (Germany)
Visual and Microperimetry Outcomes of an Extended Macular Vision IOL in Macular Atrophy
Euretina: Audio-Narrated Free Paper
"We are extremely pleased to have our EyeMax Mono™ intraocular lens included in the official programmes of these prestigious events," said Phil Marron, Chief Operations Officer at Sharpview Ophthalmology. "This is a testament to our dedication to improving the quality of life for patients with AMD. The EyeMax Mono™ IOL represents a significant advancement in ophthalmic care and the only IOP in the market designed to provide enhanced macular vision and support vision quality in AMD patients".
About Sharpview Ophthalmology
Sharpview Ophthalmology Limited is a leading innovator in the field of ophthalmology, dedicated to developing and commercialising advanced intraocular lens technology. Our mission is to enhance the quality of life for patients with age-related macular degeneration (AMD) and centrally involved macular conditions. With a commitment to research, innovation, and excellence, Sharpview Ophthalmology aims to provide cutting-edge solutions that address the unique challenges faced by patients and healthcare professionals in the field of vision care.
About EyeMax Mono
EyeMax Mono™ is a revolutionary intraocular lens (IOL) specifically designed for patients with age-related macular degeneration (AMD) and other centrally involved macular conditions. EyeMax Mono™ is uniquely designed to provide quality vision within an area up to 10° from the fovea across the macula, providing a retinal area of focus that is 4-times larger than that of other IOLs. This innovative IOL utilises advanced optical technology to improve visual acuity and overall vision quality, helping patients maintain their independence and quality of life.